" class="no-js "lang="en-US"> Aberdeen Dermatology Associates Is First in South Dakota to Offer Non-Surgical Technology for Treating Common Skin Cancers - Medtech Alert
Friday, May 24, 2024

Aberdeen Dermatology Associates Is First in South Dakota to Offer Non-Surgical Technology for Treating Common Skin Cancers

SkinCure Oncology, the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiotherapy (Image-Guided SRT), the most advanced non-surgical technology for the treatment of common skin cancers, today announced the availability of the technology in South Dakota. That state’s first installation is at Aberdeen Dermatology Associates where the announcement was made earlier today.

Image-Guided SRT is the only treatment for nonmelanoma skin cancer (basal and squamous cell carcinomas) that uses ultrasound images to help clinicians direct low-level X-ray energy to targeted areas of the skin, killing cancer cells. A study published in the peer-reviewed journal Oncology and Therapy showed that Image-Guided SRT produces a 99.3 percent cure rate, making it just as effective as traditional Mohs surgery.

“Skin cancer is prevalent in South Dakota, and we encourage everyone to get a complete body exam once a year by a board-certified dermatologist,” said Ty Hanson, D.O., director of Aberdeen Dermatology Associates. “For those dealing with common skin cancer, we are excited to provide a new, non-surgical treatment alternative. It’s covered by Medicare and most insurance plans, and it’s being recognized as the new standard of care.”

“As some 9,000 South Dakotans will likely be diagnosed with nonmelanoma skin cancer this year, we are pleased to be partnering with Aberdeen Dermatology Associates to offer a highly effective, non-surgical treatment option for their patients,” said Kerwin Brandt, CEO of SkinCure Oncology.

People In This Post

Companies In This Post

  1. Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
  2. Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
  3. DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
  4. Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
  5. Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more